Home  |  About us  |  Editorial board  |  Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 1159Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
CLINICAL RESEARCH METHODOLOGY
Year : 2011  |  Volume : 2  |  Issue : 1  |  Page : 13-22

Phase 0 clinical trials in oncology new drug development


1 Clinical Research and Medical Services, Fresenius Kabi Oncology Ltd., Gurgaon, Delhi, India
2 Medical Affairs, Novartis, Mumbai, Maharashtra, India
3 Medical Services, Merck Serono, Mumbai, Maharashtra, India

Correspondence Address:
Umesh Chandra Gupta
Clinical Research and Medical Services, Fresenius Kabi Oncology Ltd., Echelon Institutional Area, Plot no. 11, Sector 32, Gurgaon-122001, Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-3485.76285

Rights and Permissions

Research focus of pharmaceutical industry has expanded to a larger extent in last few decades putting many more new molecules, particularly targeted agents, for the clinical development. On the other hand, researchers are facing serious challenges due to high failure rates of new molecules in clinical studies. The United States Food and Drug Administration (FDA) in combination with academia and industry experts identified many factors responsible for failures of new molecules, and with a vision of taking traditional drug development model toward an innovative paradigm shift, issued regulatory guidance on conduct of exploratory investigational new drug (exploratory IND) studies, often called as phase 0 clinical trials, requiring reduced preclinical testing, which has special relevance to life-threatening diseases such as cancer. Phase 0 trials, utilizing much lower drug doses, provide an opportunity to explore the clinical behavior of new molecules very early in the drug development pathway, helping to identify the promising candidates and eliminating non-promising molecules, thus improving the efficiency of overall drug development with significant savings of resources. Being non-therapeutic in nature, these studies, however, pose certain ethical challenges requiring careful study designing and informed consent process. This article reviews the insights and perspectives for the feasibility, utility, planning, designing and conduct of phase 0 clinical trials, in addition to ethical issues and industrial perspective focused at oncology new drug development.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5354    
    Printed240    
    Emailed0    
    PDF Downloaded1427    
    Comments [Add]    
    Cited by others 3    

Recommend this journal